Huawu Biopharmaceutical synthesizes new dengue virus replication inhibitors

April 8, 2026

Huawu Biopharmaceutical Technology (Hubei) Co. Ltd. has divulged new viral replication inhibitors potentially useful for the treatment of dengue and yellow fever virus infections.

BioWorld Science Infection Patents

Today's news in brief

BioWorld

BioWorld briefs for April 9, 2026.

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

Brain with clock hands, day and night background

Lilly shifts from obesity to narcolepsy with $7.8B Centessa buy

BioWorld

Eli Lilly and Co. plans to buy Centessa Pharmaceuticals plc for $6.3 billion in up-front cash and another potential $1.5 billion through contingent value rights,...